IVIG Stops Alzheimer’s in Its Tracks

VANCOUVER — Three years of treatment with intravenous immunoglobulin (IVIG, GammaGard) prevented further cognitive decline in patients with Alzheimer’s disease, according to a small study presented here. Four patients who received the full 36 months of treatment showed no decline in scores, reported Norman Relkin, MD, of Weill Cornell Medical College in New York City.

Read more…

Comments are closed.